Penumbra, Inc. (PEN) News

Penumbra, Inc. (PEN): $220.91

7.63 (-3.34%)

POWR Rating

Component Grades








Filter PEN News Items

PEN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PEN News Highlights

  • PEN's 30 day story count now stands at 9.
  • Over the past 20 days, the trend for PEN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.

Latest PEN News From Around the Web

Below are the latest news stories about PENUMBRA INC that investors may wish to consider to help them evaluate PEN as an investment opportunity.

Wall Street Analysts See a 26.89% Upside in Penumbra (PEN): Can the Stock Really Move This High?

The mean of analysts' price targets for Penumbra (PEN) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 30, 2023

Penumbra (PEN) Enrolls First Patient in Landmark STORM-PE Trial

Penumbra (PEN) achieves an important milestone by enrolling the first patient in STORM-PE RCT.

Yahoo | November 30, 2023

Penumbra's (PEN) Expansion Moves, New Launches Aid Growth

Penumbra (PEN) expects to materially increase both revenues and profitability of the international business in the next three years and beyond.

Yahoo | November 28, 2023

First Patient in STORM-PE RCT Enrolled Evaluating Penumbra's Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash™ - for Treatment of Acute Pulmonary Embolism

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, announced the first patient enrolled in STORM-PE, a first-of-its-kind prospective, multi-center, randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus Lightning Flash™ for the treatment of pulmonary embolism (PE). In partnership with PERT Consortium™, a multi-disciplinary group dedicated to improving the care of patients with PE, the STORM-PE trial aims to advance the understan

Yahoo | November 28, 2023

Insider Sell Alert: EVP Johanna Roberts Sells Shares of Penumbra Inc

In the intricate dance of the stock market, insider transactions often attract the attention of investors seeking clues about a company's future performance.

Yahoo | November 17, 2023

Penumbra, Inc. to Present at the Piper Sandler 35th Annual Healthcare Conference

Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023.

Yahoo | November 14, 2023

Here's Why You Should Retain Penumbra (PEN) Stock for Now

Investors are optimistic about Penumbra (PEN) on strong vascular and neuro businesses growth and upbeat guidance.

Yahoo | November 14, 2023

Stocks Mixed As Bond Yields Edge Higher

Stocks are scattered this afternoon, after Moody's cut its U.S. credit rating outlook. | November 13, 2023

Penumbra Teams Up with Honor Everywhere to Bring US War Memorials to Aging Veterans

Everyday, memories of the people who served in World War II, Vietnam, and the Korean War are disappearing from living history. Virtual reality companies from around the world have teamed up in a program called "Honor Everywhere" to ensure the memorials are still accessible to these aging and terminally ill men and women via immersive stories.

Yahoo | November 10, 2023

Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase

Penumbra's (PEN) vascular and neuro product categories continue to show encouraging growth trends.

Yahoo | November 3, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!